Anti-obesity, Antiatherogenic, Anti-diabetic and Antioxidant Activities of J. montana Ethanolic Formulation in Obese Diabetic Rats Fed High-fat Diet
Keywords:J. montana, Anti-obesity, Type 2 diabetes mellitus, Glucose, Insulin resistance index, Atherogenic index
J. montana extract in the form of ethanolic formulation is rich in polyphenols, mono- and sesquiterpenes, Essential oils, flavonoids, tri- tetra- and pentamethoxy quercetin derivatives. The present study was designed to investigate the antiobesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana using obese diabetic rats’ model. Rats received either regular diet, high-fat diet or high-fat diet with additional J. montana (150 and 300 mg/kg bw) for 8 weeks. In the preventive experiment, J. montana co-administered with a high fat diet significantly inhibited body weight gain, blood glucose, triglyceride, total cholesterol, LDL-C, vLDL-C, HDL-C, free fatty acid and atherogenic index levels in a dose dependent manner. J. montana-treated rats at doses of 150 and 300 mg/kg improved the insulin resistance index when compared to the high fat diet (HFD) control. Finally, the present study is designed to evaluate the effect of ethanolic extract of J. montana on figh fat diet induce obesity in rats. J. montana treatment (150 and 300 mg/kg bw) for 8 consecutive weeks prior to obese rats administration significantly prevented the decrease in the levels of hepatic oxidative stress biomarkers reduced Glutathione (GSH), Glutathione peroxidase (GPx), Glutathione reductase (GR), Superoxide dismutase (SOD) and Catalase (CAT). The J. montana extract, also exhibited its capacity to prevent the elevated thiobarbituric acid reactive substances (TBARS) in the liver tissue. In conclusion, the anti-obesity actions of J. montana are considered attributable to increased expression of energy expenditure-related fatty liver degradation, and decreased fatty acid synthesis and fat intake in the liver. Taken together, J. montana has potential as a preventive agent for type 2 diabetes mellitus (and possibly obesity) and deserves clinical trial in the near future.